JoAnn Buczek-Thomas

Dr. JoAnn Buczek-Thomas

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2008 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
KFKimberly Forsten-Williams
Kimberly Forsten-Williams
CCChia Lin Chu
Chia Lin Chu
MFMichael Fannon
Michael Fannon
JBJoAnn Buczek-Thomas
JoAnn Buczek-Thomas
MNMatthew A. Nugent
Matthew A. Nugent

15 April 2004 in Biochemical Journal
Verified
Journal Article
Closed access
CCChia Lin Chu
Chia Lin Chu
JBJoAnn Buczek-Thomas
JoAnn Buczek-Thomas
MNMatthew A. Nugent
Matthew A. Nugent
We investigated how lipid raft association of HSPG (heparan sulphate proteoglycans) modulates FGF-2 (fibroblast growth factor-2/basic fibroblast growth factor) interactions with vascular smooth-muscle cells. When lipid rafts were disrupted with sterol-binding agents, methyl-β-cyclodextrin and filipin, FGF-2 binding to HSPG was reduced 2–5-fold, yet the amount and turnover of cell-surface HSPG were unaffected. Approx. 50–65% of bound FGF-2 was in lipid raft-associated fractions based on insolubility in cold Triton X-100 and flotation in OptiPrep density gradients, and this level was increased with higher FGF-2 concentrations. Less FGF-2 (50–90%) was associated in raft fractions when cholesterol was depleted or HSPG were degraded with heparinase III. To investigate how lipid raft–HSPG interactions altered binding, we compared the rates of FGF-2 dissociation with native, MβCD (methyl-β-cyclodextrin)- and filipin-treated cells. We found that FGF-2 dissociation rates were increased when lipid rafts were disrupted. These results suggest that localization of HSPG within lipid rafts creates high local concentrations of binding sites such that dissociation of FGF-2 is hindered. The localization of FGF-2 and HSPG to lipid rafts also correlated with the activation of protein kinase Cα. Thus raft association of HSPG might create growth factor traps resulting in increased binding and signal transduction to enhance cell sensitivity.

21 August 2008 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
JBJoAnn Buczek-Thomas
JoAnn Buczek-Thomas
EHEdward Hsia
Edward Hsia
CRCeleste B. Rich
Celeste B. Rich
JFJudith A. Foster
Judith A. Foster
MNMatthew A. Nugent
Matthew A. Nugent

1 October 1995 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YNY Nishio
Y Nishio
CWC E Warren
C E Warren
JBJoAnn Buczek-Thomas
JoAnn Buczek-Thomas
JRJ Rulfs
J Rulfs
DKD Koya
D Koya
GKG L King
G L King
Primary cardiac abnormalities have been frequently reported in patients with diabetes probably due to metabolic consequences of the disease. Approximately 2,000 mRNA species from the heart of streptozotocin-induced diabetic and control rats were compared by the mRNA differential display method, two of eight candidate clones thus isolated (DH1 and 13) were confirmed by Northern blot analysis. The expression of clone 13 was increased in the heart by 3.5-fold (P < 0.05) and decreased in the aorta by twofold (P < 0.05) in diabetes as compared to control. Sequence analysis showed that clone 13 is a rat mitochondrial gene. DH1 was predominantly expressed in the heart with an expression level 6.8-fold higher in the diabetic rats than in control (P < 0.001). Insulin treatment significantly (P < 0.001) normalized the expression of DH1 in the hearts of diabetic rats. DH1 expression was observed in cultured rat cardiomyocytes, but not in aortic smooth muscle cells or in cardiac derived fibroblasts. The expression in cardiomyocytes was regulated by insulin and glucose concentration of culture media. The full length cDNA of DH1 had a single open-reading frame with 85 and 92% amino acid identity to human and mouse UDP-GlcNAc:Gal beta 1-3GalNAc alpha R beta 1-6 N-acetylglucosaminyltransferase (core 2 GlcNAc-T), respectively, a key enzyme determining the structure of O-linked glycosylation. Transient transfection of DH1 cDNA into Cos7 cells conferred core 2 GlcNAc-T enzyme activity. In vivo, core 2 GlcNAc-T activity was increased by 82% (P < 0.05) in diabetic hearts vs controls, while the enzymes GlcNAc-TI and GlcNAc-TV responsible for N-linked glycosylation were unchanged. These results suggest that core 2 GlcNAc-T is specifically induced in the heart by diabetes or hyperglycemia. The induction of this enzyme may be responsible for the increase in the deposition of glycoconjugates and the abnormal functions found in the hearts of diabetic rats.

1 August 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JBJoAnn Buczek-Thomas
JoAnn Buczek-Thomas
MNMatthew A. Nugent
Matthew A. Nugent
We have investigated elastase-mediated alterations in the expression of basic fibroblast growth factor (bFGF) receptors and proteoglycan co-receptors and characterized the subsequent effects on bFGF receptor binding profiles. For these studies, pulmonary fibroblast cultures were treated with porcine pancreatic elastase, and elastase-mediated changes in bFGF receptor expression and binding profiles were assessed. Quantitation of [(35)S]sulfate-labeled proteoglycan and total glycosaminoglycan release from fibroblast matrices indicated that elastase treatment released sulfated proteoglycan from the cell surface in a time- and dose-dependent fashion that correlated strongly with elastase-mediated bFGF release. Ligand binding studies indicated that elastase treatment decreased total binding of (125)I-bFGF to the cell surface and affected both fibroblast growth factor receptor and heparan sulfate proteoglycan (HSPG) binding sites. Western blot analyses indicated that elastase treatment did not release significant amounts of fibroblast growth factor receptor protein. These findings indicate that elastase-mediated HSPG release from fibroblast matrices reduces the effective affinity of bFGF for its receptor. Collectively, these studies suggest that HSPG co-receptors are important mediators of the pulmonary fibroblast response to elastase treatment and that bFGF, HSPG, and other elastase-released entities play an important role in the response of the lung to chronic injury.

1 September 2004 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
JBJoAnn Buczek-Thomas
JoAnn Buczek-Thomas
ELEdgar C. Lucey
Edgar C. Lucey
PSPhillip J. Stone
Phillip J. Stone
CCChia L. Chu
Chia L. Chu
CRCeleste B. Rich
Celeste B. Rich
MNMatthew A. Nugent
Matthew A. Nugent
Uncontrolled elastase activity is involved in the development of several types of lung disease. Previous reports demonstrated that growth factors are liberated from pulmonary matrix storage sites by elastase; however, release of these entities in vivo is not well defined. In the present study, we investigated the release of fibroblast growth factor-2 (FGF-2) and transforming growth factor-beta (TGF-beta), after intratracheal instillation of porcine pancreatic elastase into mice. We found that elastase promoted a time-dependent release of FGF-2 and TGF-beta1 from the lung into bronchoalveolar lavage (BAL) fluid. A large fraction of the TGF-beta1 in BAL fluid was in the active form (approximately 60%), suggesting that elastase might participate in the activation of TGF-beta1 from its latent form. Analysis of the levels of FGF-2 and TGF-beta1 in mouse blood indicated that the growth factors in BAL fluid were not entirely derived from blood. Moreover, elastase treatment of pulmonary fibroblasts cultures caused the release of TGF-beta1, suggesting that the TGF-beta1 in BAL fluid could have come from lung cells/matrix. Additional in vitro studies also indicated that TGF-beta1 plays a role in upregulating elastin mRNA levels. These data suggest that elastase releases growth factors from lung that participate in elastolytic injury responses.